AU2022348907B2 - Methods of treating myelodysplastic syndromes with decitabine and cedazuridine - Google Patents

Methods of treating myelodysplastic syndromes with decitabine and cedazuridine

Info

Publication number
AU2022348907B2
AU2022348907B2 AU2022348907A AU2022348907A AU2022348907B2 AU 2022348907 B2 AU2022348907 B2 AU 2022348907B2 AU 2022348907 A AU2022348907 A AU 2022348907A AU 2022348907 A AU2022348907 A AU 2022348907A AU 2022348907 B2 AU2022348907 B2 AU 2022348907B2
Authority
AU
Australia
Prior art keywords
decitabine
cedazuridine
subject
mds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022348907A
Other languages
English (en)
Other versions
AU2022348907A1 (en
Inventor
Mohammad Azab
Yong Hao
Harold Keer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2022348907A1 publication Critical patent/AU2022348907A1/en
Assigned to TAIHO PHARMACEUTICAL CO., LTD. reassignment TAIHO PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: OTSUKA PHARMACEUTICAL CO., LTD.
Application granted granted Critical
Publication of AU2022348907B2 publication Critical patent/AU2022348907B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022348907A 2021-09-21 2022-09-21 Methods of treating myelodysplastic syndromes with decitabine and cedazuridine Active AU2022348907B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246547P 2021-09-21 2021-09-21
US63/246,547 2021-09-21
PCT/US2022/076757 WO2023049731A2 (en) 2021-09-21 2022-09-21 Methods of treating myelodysplastic syndromes with decitabine and cedazuridine

Publications (2)

Publication Number Publication Date
AU2022348907A1 AU2022348907A1 (en) 2024-04-11
AU2022348907B2 true AU2022348907B2 (en) 2026-07-16

Family

ID=85721229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022348907A Active AU2022348907B2 (en) 2021-09-21 2022-09-21 Methods of treating myelodysplastic syndromes with decitabine and cedazuridine

Country Status (10)

Country Link
US (1) US20250000888A1 (cg-RX-API-DMAC7.html)
EP (1) EP4404940A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024531799A (cg-RX-API-DMAC7.html)
KR (1) KR20240064656A (cg-RX-API-DMAC7.html)
CN (1) CN118201622A (cg-RX-API-DMAC7.html)
AU (1) AU2022348907B2 (cg-RX-API-DMAC7.html)
CA (1) CA3232623A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003537A (cg-RX-API-DMAC7.html)
TW (1) TW202327625A (cg-RX-API-DMAC7.html)
WO (1) WO2023049731A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085848A1 (en) * 2018-09-19 2020-03-19 Otsuka Pharmaceutical Co., Ltd. Low dose combination cda substrate drug/cedazuridine with extended administration
WO2021113688A1 (en) * 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
WO2021144657A1 (en) * 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021173598A1 (en) * 2020-02-25 2021-09-02 Otsuka Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) * 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US10683552B2 (en) * 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085848A1 (en) * 2018-09-19 2020-03-19 Otsuka Pharmaceutical Co., Ltd. Low dose combination cda substrate drug/cedazuridine with extended administration
WO2021113688A1 (en) * 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
WO2021144657A1 (en) * 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021173598A1 (en) * 2020-02-25 2021-09-02 Otsuka Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms

Also Published As

Publication number Publication date
JP2024531799A (ja) 2024-08-29
US20250000888A1 (en) 2025-01-02
WO2023049731A2 (en) 2023-03-30
AU2022348907A1 (en) 2024-04-11
WO2023049731A3 (en) 2023-05-04
TW202327625A (zh) 2023-07-16
CN118201622A (zh) 2024-06-14
EP4404940A4 (en) 2025-07-30
MX2024003537A (es) 2024-05-03
EP4404940A2 (en) 2024-07-31
CA3232623A1 (en) 2023-03-30
KR20240064656A (ko) 2024-05-13

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAIHO PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): OTSUKA PHARMACEUTICAL CO., LTD.